A Multicenter Randomized, Open-label Study to Compare the Efficacy of Subcutaneous Infliximab Monotherapy with Subcutaneous Infliximab and Concomitant Immunosuppression in the Treatment of Moderate to Severe Crohn's Disease
Latest Information Update: 12 Dec 2024
At a glance
- Drugs Azathioprine (Primary) ; Infliximab (Primary) ; Mercaptopurine (Primary) ; Methotrexate (Primary) ; Tioguanine (Primary) ; Folic acid
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms DIRECTCD
Most Recent Events
- 10 Dec 2024 Planned End Date changed from 1 Jul 2024 to 1 Dec 2025.
- 10 Dec 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jun 2025.
- 03 Oct 2023 New trial record